Discover Clinical Trials at City of Hope
Use the search and filter features below to discover and explore relevant clinical trials underway at City of Hope®. Please reach out to your cancer care team who can help you find out whether you qualify for any of our open clinical trials.
465 results
A Phase III Trial of Stereotactic Radiosurgery compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT)Plus Memantine for 5-15 Brain Metastases
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain.
Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hippocampus is a brain structure that is important for memory. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms.
Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.
Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hippocampus is a brain structure that is important for memory. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms.
Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.
Location Name
Status
Antelope Valley
Open to Accrual
Corona
Open to Accrual
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
South Bay
Open to Accrual
South Pasadena
Open to Accrual
Upland
Open to Accrual
Acellular Dermal Matrix Investigation in Breast Reconstruction (ADMIRE Study)
Prospective, multi-center, dual-arm non-randomized clinical study in females undergoing a two-stage breast reconstruction using a pre-pectoral technique.
Location Name
Status
Duarte
Open to Accrual
Open to Accrual
International Myeloma Foundation Study of the Outcomes of Patients with Relapsed or High-Risk Myeloma Receiving Novel Immunotherapies
Location Name
Status
Atlanta
Open to Accrual
Chicago
Closed to Accrual
Duarte
Open to Accrual
Huntington Beach
Closed to Accrual
Lennar Foundation Cancer Center
Open to Accrual
Phoenix
Open to Accrual
Sand Canyon
Open to Accrual
Seacliff
Open to Accrual
A Phase II Study of the Non-covalent BTK Inhibitor Nemtabrutinib in Combination with the CD20 Monoclonal Antibody Rituximab in Patients with Marginal Zone Lymphoma
This phase II trial tests the effect of nemtabrutinib in combination with rituximab in treating patients with marginal zone lymphoma. Nemtabrutinib, a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nemtabrutinib in combination with rituximab may be safe, tolerable and/or effective in treating patients with marginal zone lymphoma.
Location Name
Status
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Pending
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion Dependent Anemia in Adult Participants with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.
Location Name
Status
Antelope Valley
Closed to Accrual
Corona
Open to Accrual
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Closed to Accrual
Long Beach Elm
Closed to Accrual
Newport Beach Lido
Closed to Accrual
Seacliff
Open to Accrual
South Pasadena
Closed to Accrual
Upland
Open to Accrual
DOse Reduction Of DoceTaxol-Based cHemotherapY in Vulnerable Older Women with Early-Stage Breast Cancer (DOROTHY)
This phase II trial tests how well dose-reduced docetaxel combined with cyclophosphamide works in treating older women with early stage (stage I-III) HER2 negative breast cancer vulnerable to toxicity. Chemotherapy drugs, such as docetaxel and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Docetaxel and cyclophosphamide are commonly used, but is not well tolerated at the standard dose and can affect the way older patients feel physically and emotionally. Giving dose-reduced docetaxel combined with cyclophosphamide may be an effective treatment option and improve quality of life in vulnerable older women with stage I-III HER2 negative breast cancer.
Location Name
Status
Antelope Valley
Open to Accrual
Corona
Open to Accrual
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
Newport Beach Lido
Pending
Seacliff
Open to Accrual
South Bay
Open to Accrual
South Pasadena
Open to Accrual
Upland
Open to Accrual
A Long-Term Safety Follow-Up Study for Patients Treated with Anti-CD7 Allogeneic Car-T Cells (WU-CART-007)
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.
Location Name
Status
Duarte
Open to Accrual
A single-center pilot study using TCRa/B and CD45RA depleted stem cell grafts from
haploidentical donors for hematopoietic cell transplantation in adults (HAPLO 2022)
haploidentical donors for hematopoietic cell transplantation in adults (HAPLO 2022)
This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
Location Name
Status
Duarte
Open to Accrual
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Location Name
Status
Antelope Valley
Suspended
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
Long Beach Elm
Open to Accrual
South Pasadena
Open to Accrual
Upland
Open to Accrual
Phase Ib Study To Evaluate Humanized CD19-Specific CAR T Cells Following Lymphodepleting Chemotherapy In Adult Patients With Relapsed/ Refractory CD19+ B- Cell Acute Lymphoblastic Leukemia
This phase Ib trial tests the safety, side effects, and effectiveness of humanized (hu)CD19-chimeric antigen receptor (CAR) T cell therapy in treating patients with CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR T-cell therapy is a treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as CD19, on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the huCD19 positive CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Chemotherapy drugs, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. huCD19-CAR T cell therapy may be safe, tolerable and effective in treating patients with relapsed or refractory CD19 positive ALL.
Location Name
Status
Duarte
Suspended
Note: Some clinical trials at City of Hope may not be listed. Please reach out to your cancer care team to identify additional trials for which you may qualify.